This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer's Head Fake:

NEW YORK (TheStreet) -- AstraZeneca (AZN - Get Report) and Pfizer (PFE - Get Report) investors held their breath Friday after Pfizer trading was briefly halted for news. Many investors anticipated that, after months of pursuit, Pfizer had won over AstraZeneca with a suitable offer.

But it was not to be.

lol, $PFE news not related to $AZN. thanks for playing!

? Aron Pinson (@MicroFundy) May. 16 at 12:12 PM

Instead of announcing a merger, Pfizer unveiled a new drug. The pharmaceutical giant said it would submit a new treatment for post-menopausal women with breast cancer. The new medication, called palbociclib, successfully blocked tumor growth when combined with another cancer drug letrozole in trials. The combined treatment proved better than letrozole alone.

@reefcap PFE is announcing they are submitting an NDA early for a cancer drug that has been in trials. No M/A stuff unfortunately.

? Michael (@YazzJr) May. 16 at 12:25 PM

Pfizer shares climbed more than 1% on the news. AstraZeneca edged higher.

Pfizer sweetened its offer for AstraZeneca last week to $84.47-per-share. This week, management shared a presentation displaying the benefits a combined company would enjoy and questioning AstraZeneca's ability to go it alone.

"The Board of AstraZeneca believes Pfizer is making an opportunistic attempt to acquire a transformed AstraZeneca without reflecting the value of its existing pipeline," management said in a statement this week. "The Board reiterates its confidence in AstraZeneca's ability to deliver on its prospects as an independent, science led business."

AstraZeneca has several drugs in its pipeline that it believes could be blockbusters, including three drugs to treat ovarian cancer and two to treat thyroid cancer. It also has several other cancer drugs in late stage development as well as treatments for asthma, arthritis, serious infections and diabetes, among other diseases. But Pfizer says those drugs don't warrant more than $106 billion.

In its presentation, released May 13, Pfizer made the case that AstraZeneca faces challenges that mitigate the potential value of its pipeline. The company said that AstraZeneca faces lost revenues of $14 billion when major drug patents expire in the near term. Pfizer also said that AstraZeneca's late stage pipeline is not differentiated enough and its early stage pipeline has many risks.

Some investors said Friday that, should AstraZeneca keep playing hardball, Pfizer is likely to walk away.

$PFE Guessing they tell $AZN to rot in hell!!!

? MrX (@MrX) May. 16 at 12:08 PM

But others believe that the merger could still happen. In its presentation, Pfizer indicated that it could hike the offer, yet again, if AstraZeneca management convinced it of the value of pipeline drugs.

"Pfizer believes there is compelling rationale for a combination and if AstraZeneca engages in conversations to provide Pfizer with a better understanding of its business and its prospects it may lead to a transaction that AstraZeneca can recommend."

At the time of publication the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $28.25 -2.30%
PFE $33.58 -0.36%
AAPL $94.23 -1.00%
GOOG $698.20 0.84%
FB $118.05 0.53%


Chart of I:DJI
DOW 17,651.09 -99.82 -0.56%
S&P 500 2,049.79 -13.58 -0.66%
NASDAQ 4,726.5910 -36.6330 -0.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs